Physician profile
Bing Liao
NPI 1932488368
$4,028.05
in general payments reported to CMS, 2019-2025
26 companies · $992 in 2025
The $992 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.75 · 2020: $349 · 2021: $135 · 2022: $234 · 2023: $1,875 · 2024: $381 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986 · Consulting Fee: $1,188 · Education: $74.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.84 |
| Consulting Fee | $1,188.00 |
| Education | $74.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $1,468.34 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $376.98 | 2020-2025 | Ultomiris |
| Abbvie INC. | $350.32 | 2021-2025 | |
| Pfizer INC. | $302.89 | 2022-2025 | |
| Ucb, INC. | $218.68 | 2023-2025 | Rystiggo |
| Csl Behring | $176.35 | 2019-2025 | Hizentra |
| Allergan, INC. | $154.86 | 2020-2022 | |
| Hospira, INC. | $153.03 | 2024-2025 | |
| Averitas Pharma INC. | $104.41 | 2025 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $103.05 | 2023-2025 | Hyqvia |
| Emd Serono, INC. | $91.15 | 2022-2025 | |
| Amgen INC. | $87.11 | 2020-2025 | Uplizna |
| Grifols USA, LLC | $66.55 | 2019-2025 | Gamunex-C, Xembify |
| Catalyst Pharmaceuticals, INC. | $62.09 | 2020-2024 | |
| Tanabe Pharma America, INC. | $56.88 | 2020-2025 | Radicava |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $50.39 | 2021-2024 | Vumerity, Tysabri |
| Ge Healthcare | $31.73 | 2023 | |
| Novartis Pharmaceuticals Corporation | $30.00 | 2023 | |
| Springworks Therapeutics, INC. | $26.62 | 2025 | Gomekli |
| Eisai INC. | $24.37 | 2023 | |
| Amicus Therapeutics, INC. | $20.00 | 2024 | Pombiliti, Opfolda |
| Grt US Holding, INC. | $17.08 | 2020 | |
| Neurocrine Biosciences, INC. | $14.87 | 2019 | |
| Merz North America, INC. | $14.24 | 2020 | |
| Genzyme Corporation | $13.99 | 2020 | |
| Lundbeck LLC | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bing Liao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.